Injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules is effective in reducing nodule hardness and nodule size. Researchers at the Kennedy Institute, University of Oxford, led by ...

Results of a phase 2b trial led by researchers at Oxford University’s Kennedy Institute have shown that the anti-TNF drug adalimumab is effective for treating early-stage Dupuytren's disease.

Ventoux Biosciences, a San Diego–based company that aims to treat fibrotic diseases such as Dupuytren’s, has launched. Surgery is the current standard of care for Dupuytren’s disease, an inheritable ...

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early-stage Dupuytren's ...

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Dupuytren's Disease Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ...

Please provide your email address to receive an email when new articles are posted on . Researchers used online surveys to determine whether consensus could be reached among 20 hand surgeons with ...

Dupuytren contracture is a disorder that can cause the fingers to curl in, primarily the ring and small fingers. It’s a genetic condition mostly affecting men over 60 of Northern European descent.

video: Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size providing hope to patients. view more Researchers at the ...